Drug Target Discovery and Integration

Drug Target was discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology. After sequencing of the human genome allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease-modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy. Modern drug discovery and Integration involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability

  • therapeutic effect
  • hypothesized
  • pharmacology

Related Conference of Drug Target Discovery and Integration

March 18-19, 2024

20th International Conference on Cancer Research

Zurich, Switzerland
April 24-25, 2024

33rd Neonatology and Primary Care Congress

Paris, France
April 30-30, 2024

14th International Conference on Womens Health and Cancer Cure

Amsterdam, Netherlands
July 25-26, 2024

20th World Summit on Blockchain Technology

Amsterdam, Netherlands
August 20-21, 2024

11th World Summit on Epilepsy and Bipolar Disorders

Montreal, Canada

Drug Target Discovery and Integration Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in